- Exchange: EN Amsterdam
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Galapagos NV (GLPGA)
| Open: | - | Day's Range: | - | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 4.8500 | 52wk Range: | - | 1-Yr Rtn: | - |
Key Statistics for GLPGA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | 285.2941 |
| Relative P/E vs. AEX | - |
| Earnings Per Share (EUR) (ttm) | - |
| Est. EPS (EUR) (12/2013) | 0.0170 |
| Est. PEG Ratio | 3.8710 |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 26.42 |
| 30 Day Average Volume | - |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GLPGA
Company Profile & Key Executives for GLPGA
Galapagos NV is a drug discovery company focused on the identification of disease modifying drug targets. The Company specializes in osteoporosis, rheumatoid arthritis, osteoarthritis and Alzheimer's disease.
| Onno Van De StolpeCEO/Executive Director | Guillaume JettenChief Financial Officer |
| Piet WigerinckChief Scientific Officer | Chris NewtonSenior VP:Galapagos Services |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
GLPGA News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page